When you know more about your disease, you can use what you’ve learned to talk to your doctor to decide the best treatment options for you and make a treatment plan together.

Through the Patient Gateways, you will be able to learn more about your type of lung cancer and get resources that help guide you through your experience with lung cancer. There are also tools that help you find a specialist and clinical trials, connect you with other people with your type of lung cancer, and sign up for a newsletter to keep you up to date on the latest research and news specific to your type of lung cancer.

Choose your site below. Not sure of your type of lung cancer? Find out more about biomarker testing.

KRAS

Up to 1 out of 3 patients with NSCLC
(about 25-30%) have a KRAS mutation.

Learn More
KRAS

Non-Small Cell Lung Cancer

About 85% of all lung cancers are non-small cell lung cancer.

Learn More
Non-Small Cell Lung Cancer

ALK

ALK-positive lung cancer represents about 4% of lung cancer in NSCLC.

Learn More
ALK

EGFR

EGFR-positive lung cancer represents about 10-15% of lung cancer in the U.S. and generally appears in NSCLC.

Learn More
EGFR

Rare Mutations and Fusions

(ROS1, MET, RET, NTRK, BRAF, others)

Insights into rare mutations in NSCLC may offer information for understanding and treating these types of biomarkers.

Learn More
Rare Mutations and Fusions

Small Cell Lung Cancer

Small cell lung cancer accounts for 15% of all lung cancers.

Learn More
Small Cell Lung Cancer

Thank You

to Amgen for their generous contribution to our Gateway Program

amgen logo

 

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Learn More